| Ident. | Authors (with country if any) | Title |
|---|
| 000010 |
YOUN JU LEE [Corée du Sud] ; So-Young Choi [Corée du Sud] ; Jae H. Yang [Corée du Sud] | NMDA receptor-mediated ERK 1/2 pathway is involved in PFHxS-induced apoptosis of PC12 cells |
| 000068 |
Danielle Murray [Canada] ; A. Jon Stoessl [Canada] | Mechanisms and therapeutic implications of the placebo effect in neurological and psychiatric conditions |
| 000225 |
Amit Bar-Or [Canada] ; Peter Rieckmann [Canada] ; Anthony Traboulsee [Canada] ; V. Wee Yong [Canada] | Targeting Progressive Neuroaxonal Injury: Lessons from Multiple Sclerosis |
| 000433 |
M. Bousquet [Canada] ; C. Gibrat [Canada] ; M. Saint-Pierre [Canada] ; C. Julien [Canada] ; F. Calon [Canada] ; F. Cicchetti [Canada] | Modulation of brain-derived neurotrophic factor as a potential neuroprotective mechanism of action of omega-3 fatty acids in a parkinsonian animal model |
| 000782 |
Shawn Hayley [Canada] ; Hymie Anisman [Canada] | Multiple mechanisms of cytokine action in neurodegenerative and psychiatric states: Neurochemical and molecular substrates : The role of cytokines in neurodegeneration and psychiatric conditions: Multiple mechanisms of action |
| 000971 |
Frédéric Calon [Canada] ; Marc Morissette [Canada] ; Ali H. Rajput [Canada] ; Oleh Hornykiewicz [Canada, Autriche] ; Paul J. Bedard [Canada] ; Thérèse Di Paolo [Canada] | Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications |
| 000972 |
Antonio P. Strafella [Canada] ; Alain Dagher [Canada] ; Abbas F. Sadikot [Canada] | Cerebral blood flow changes induced by subthalamic stimulation in Parkinson's disease |
| 000989 |
H. Uri Saragovi [Canada] ; Maria Clara Zaccaro [Canada] | Small molecule peptidomimetic ligands of neurotrophin receptors, identifying binding sites, activation sites and regulatory sites |
| 000A07 |
Jonathan O. Dostrovsky [Canada] ; Andres M. Lozano [Canada] | Mechanisms of deep brain stimulation |
| 000A22 |
Michel Cyr [Canada] ; Frederic Calon [Canada] ; Marc Morissette [Canada] ; Thérèse Di Paolo [Canada] | Estrogenic modulation of brain activity: implications for schizophrenia and Parkinson's disease |
| 000A50 |
Wakako Maruyama [Japon] ; Yukihiro Akao [Japon] ; Moussa B. H. Youdim [Israël] ; Bruce A. Davis [Canada] ; Makoto Naoi [Japon] | Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol |
| 000B18 |
Y. R. Wu [Taïwan] ; R. Levy [Canada] ; P. Ashby [Canada] ; R. R. Tasker [Canada] ; J. O. Dostrovsky [Canada] | Does stimulation of the GPi control dyskinesia by activating inhibitory axons? |
| 000B60 |
M. Goulet [Canada] ; R. Grondin [Canada] ; M. Morissette [Canada] ; S. Maltais [Canada] ; P. Falardeau [Canada] ; P. J. Bedard [Canada] ; T. Di Paolo [Canada] | Regulation by chronic treatment with cabergoline of dopamine D1 and D2 receptor levels and their expression in the striatum of Parkinsonian-Monkeys |
| 000B63 |
Andis Klegeris [Canada] ; Patrick L. Mcgeer [Canada] | R-(-)-deprenyl inhibits monocytic THP-1 cell neurotoxicity independently of monoamine oxidase inhibition |
| 000B96 |
M. Cyr [Canada] ; F. Calon [Canada] ; M. Morissette [Canada] ; M. Grandbois [Canada] ; S. Callier [Canada, France] ; T. Di Paolo [Canada] | Drugs with estrogen-like potency and brain activity : Potential therapeutic application for the CNS |
| 000C44 |
P. Ashby [Canada] ; Y. J. Kim [Canada] ; R. Kumar [Canada] ; A. E. Lang [Canada] ; A. M. Lozano [Canada] | Neurophysiological effects of stimulation through electrodes in the human subthalamic nucleus |
| 000C65 |
R. Grondin [Canada] ; V. D. Doan ; L. Gregoire ; P. J. Bedard | D1 receptor blockade improves L-dopa-induced dyskinesia but worsens parkinsonism in MPTP monkeys |
| 000C83 |
E. G. Mcgeer [Canada] ; P. L. Mcgeer [Canada] | The future use of complement inhibitors for the treatment of neurological diseases |
| 000C90 |
A. Samii [Canada] ; S. R. Letwin [Canada] ; D. B. Calne [Canada] | Prospects for new drug treatment in idiopathic parkinsonism |
| 000D40 |
| Pallidotomie |
| 000D60 |
C.-T. Lai [Canada] ; P. H. Yu [Canada] | R(-)-deprenyl potentiates dopamine induced cytotoxicity toward catecholaminergic neuroblastoma SH-SY5Y cells |
| 000E16 |
W. G. Tatton [Canada] ; R. M. E. Chalmers-Redman [Canada] | Modulation of gene expression rather than monoamine oxidase inhibition : (-)-Deprenyl-related compounds in controlling neurodegeneration |
| 000E23 |
D. Boismenu [Canada] ; O. Mamer [Canada] ; L. Ste-Marie [Canada] ; L. Vachon [Canada] ; J. Montgomery [Canada] | In vivo hydroxylation of the neurotoxin, 1-methyl-4-phenylpyridinium, and the effect of monoamine oxidase inhibitors : Electrospray-MS analysis of intra-striatal microdialysates |
| 000E48 |
J.-A. St-Pierre [Canada] ; P. J. Bedard | Systemic administration of the NMDA receptor antagonist MK-801 potentiates circling induced by intrastriatal microinjection of dopamine |
| 000E60 |
P. J. Blanchet ; B. Gomez-Mancilla [Canada] ; T. Di Paolo ; P. J. Bedard | Is striatal dopaminergic receptor imbalance responsible for levodopa-induced dyskinesia ? |
| 000E66 |
C. Gagnon [Canada] ; B. Gomez-Mancilla ; R. Markstein ; P. J. Bedard ; T. Di Paolo [Canada] | Effect of adding the D-1 agonist CY 208-243 to chronic bromocriptine treatment of MPTP-monkeys : regional changes of brain dopamine receptors |
| 000E88 |
E. Scarr [Canada] ; D. M. Wingerchuk ; A. V. Juorio ; I. A. Paterson | The effects of monoamine oxidase B inhibition on dopamine metabolism in rats with nigro-striatal lesions |
| 000F45 |
P. Blanchet [Canada] ; P. J. Bedard [Canada] ; D. R. Britton ; J. W. Kebabian | Differential effect of selective D-1 and D-2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-exposed monkeys |
| 000F55 |
J. Poirier [Canada] ; C. Thiffault | Are free radicals involved in the pathogenesis of idiopathic Parkinson's disease ? |
| 001015 |
W. G. Tatton [Canada] ; C. E. Greenwood | Rescue of dying neurons : a new action for deprenyl in MPTP parkinsonism |
| 001031 |
B. Gomez-Mancilla [Canada] ; P. J. Bedard | Effect of D1 and D2 agonists and antagonists on dyskinesia produced by L-DOPA in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys |
| 001093 |
G. S. Robertson ; D. G. Herrera ; M. Dragunow ; H. A. Robertson | L-DOPA activates c-fos in the striatum ipsilateral to a 6-hydroxydopamine lesion of the substantia nigra |
| 001128 |
R. J. Riopelle | Adrenal medulla autografts in Parkinson's disease: a proposed mechanism of action |
| 001147 |
H. A. Robertson ; G. S. Robertson | Hypothesis. Combined L-dopa and bromocriptine therapy for Parkinson's disease: a proposed mechanism of action |
